HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.…
Is HeartSciences Inc. (HSCS) Stock Outpacing Its Medical Peers This Year?
HeartSciences (NASDAQ: HSCS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 14 employees.
The shares were at 1.810 USD on 20 November 2026, down 30.7% over 52 weeks. Its 52-week range is 1.630 USD to 5.250 USD: the price is 65.5% below the high and 11.0% above the low.
Its market capitalisation is 10.26M USD.
HeartSciences reports revenue up 10.5% year over year.
Its debt exceeds its cash by 3.97M USD, a debt-to-equity ratio of 17.41. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.